Brutalist Biotech

• Two years after Carmot buyout, what’s next for Roche’s expensive obesity pipeline? (2d)
• Chutes & Ladders—CatalYm catalyzes C-suite shakeup (2d)
• Moderna co-founder Robert Langer's son launches new VC with $77.5M, backing from dad (3d)
• Carisma’s lifeline dissipates as reverse merger plans fall through, Moderna cuts ties (3d)
• Biogen strikes $85M Alcyone buyout, securing tech for spinal drug delivery (3d)
• VectorY pens $1.2B biobucks pact to use Shape's capsid to deliver gene therapies into brain (3d)
• Pfizer, Arvinas lose interest in commercializing PROTAC inhibitor, leading to layoffs at the biotech (3d)
• Roche becomes MASH player via $3.5B deal for 89bio and its phase 3 drug (3d)
• QL Biopharm links once-monthly GLP-1 to incumbent-rivaling weight loss in phase 2 (3d)
• ArsenalBio lays off 50% of staff in pivot from early-stage research (3d)

• CDC panel, recast by RFK Jr., softens COVID vaccine recommendations (1d)
• Arvinas reboots, cuts more staff; Porges joins Lazard (2d)
• CDC advisers postpone vote to delay some newborns’ hepatitis B shot (2d)
• CDC panel recommends splitting measles, varicella shots (2d)
• A new biotech venture firm emerges, led by Bob Langer’s son (3d)
• Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs (3d)
• Roche dives into MASH with $2.4B deal for 89bio (3d)
• Fired CDC director says RFK Jr. aims to change childhood vaccine schedule (4d)
• Roivant pill succeeds in rare inflammatory disease trial (4d)
• GSK ups US investment with $30B spending plan (4d)

• This year’s Endpoints 11 winners; Monarez testifies to Congress; Eli Lilly’s obesity pill lags; and more (1d)
• MapLight prepares for IPO to back schizophrenia, Alzheimer's drug (1d)
• ACIP recommends that people consult a provider before getting Covid shots (1d)
• Merck wins approval of subcutaneous Keytruda, in bid to extend life of world's top-selling drug (2d)
• Regeneron’s Lynozyfic yields 100% response rate in small smoldering multiple myeloma study (2d)
• CHMP recommends Novo's weekly diabetes injection, Bayer's menopause drug (2d)
• CDC vaccine advisors shelve vote on hepatitis B birth dose (2d)
• Endpoints 11 winner 2025: Chai Discovery aims to design drugs on the computer (2d)
• The 2025 winners of the Endpoints 11: Biotech's most exciting startups (2d)
• Endpoints 11 winner 2025: Umoja Biopharma hopes to break CAR-T's in vivo barrier (2d)

• ACIP Day 2 Reveals Confusion, ‘Lack of Knowledge,’ on Revamped Committee (1d)
• Bye Bye Bluebird: Gene Therapy Biotech Emerges From Private Buyout With Rebrand (2d)
• Reformed ACIP Recommends Delaying MMRV Combo Vaccination, Forecasts Changes to Hep B, COVID (2d)
• Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer (2d)
• Hope for Rare Pediatric Disease Voucher Reignited as House Bill Passes Committee (2d)
• Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered (2d)
• VectorY Bets up to $1.2B+ That Shape’s Brain-Penetrant Capsids Are a Fit (3d)
• Layoffs From Just 6 Pharmas Could Wipe Out Over 39,000 Jobs (3d)
• What Do AI and Hammers Have in Common? (3d)
• Novo, BMS Layoffs Hit New Jersey Hard With More Than 500 Left Jobless (3d)

• Pro sports leagues should do away with injury reports (6h)
• Winner of mRNA Nobel Prize says ACIP member’s claim that Covid vaccines persist is “absolutely impossible” (1d)
• In a chaotic meeting, RFK Jr.’s handpicked advisers begin altering the childhood vaccine schedule (1d)
• FDA approves ultra-rare disease drug that became a symbol of uncertainty over regulatory standards (1d)
• ACA tax credits still in limbo after stopgap government funding bill fails (1d)
• Federal vaccine panel remade by RFK Jr. votes to maintain insurance coverage for Covid shots (1d)
• CDC reverses telework pause that sparked complaints over its impact on workers with disabilities (2d)
• Up and down the ladder: The latest comings and goings (2d)
• Biotech M&A’s quiet roll (2d)
• We’re reading about CVS coverage of an HIV drug, an EMA boost for Merck, and more (2d)

• Trially AI Raises $4.7M Seed Round, Launches AI for Clinical Trial Enrollment (3h)
• Helmholtz Munich and Parse Biosciences Partner to Build Largest Human Lung Tissue Perturbation Atlas (2d)
• Immuto Raises $8M Seed for AI Structural Surfaceomics, Enters Daiichi Sankyo Oncology Collaboration (2d)
• T.Rx Capital Raises $77.5M to Back Early-Stage Biotech and Digital Health (3d)
• Enveda Starts Phase 1b of AI-Discovered Small-Molecule Anti-Inflammatory for Atopic Dermatitis (3d)
• UK Health-AI Push: NVIDIA Partnerships Back Sovereign Models from Imaging to Drug Design (3d)
• Stanford–Arc Team Reports AI-Made Viruses That Kill Bacteria (3d)
• Google-Backed BenchSci Reports New System to Extract Experimental Context From Biomedical Papers Into a Traceable Evidence Graph (4d)
• Lantern Pharma Reports AI-Guided LP-184 Meets Phase 1a Endpoints in Solid Tumors (4d)
• Biomni and Sage Partner on AI-Powered Access to Biomedical Data (4d)

Drug Channels

• Cracking the Code of BIN/PCN/Group Data for Faster Benefit Verification (2d)
• Preorder Now: DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors (4d)
• Inside the 2025 PSAO Market: How Wholesalers Shape Pharmacy–PBM Relationships (5d)
• The $90 Billion Leakage Problem: How RIS Rx Helps Pharma Recover Lost Revenue (6d)
• Inside Rare Disease Pharmacy: Lessons in Personalizing Care (1w)
• Drug Channels Leadership Forum 2026: Full Agenda Now Available (Spoiler: Even more awesome than 2025!) (2w)
• If Banks Sync Data in Real Time, Why Can't Patient Services? (2w)
• Hubs: The Bridge Between Patients and Providers (3w)
• Why the Pharmacy Supply Chain Is Broken and How SmithRx Is Fixing It (1mo)
• Drug Channels News Roundup, August 2025: White Bagging Battles, Private Label Price Hypocrisy, 340B Patient Problems, and UnitedHealth Group’s Woes (1mo)

• Genfit SA discontinues lead programme (10h)
• Mondego Bio raises €20m in Series A (2d)
• Whitepaper Plastic Injection Molding in Cleanrooms (2d)
• Roche acquires 89bio for US$3.5bn (3d)
• CSL backs VarmX in US$2.2bn deal (4d)
• Enhanced Genomics raises US$19m (4d)
• Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal (5d)
• Trump dismantles FDA expert committees (6d)
• UK pharma lobby warns of crisis in British life sciences (1w)
• A Universal Solution Emerges: Anti-Linker Antibodies Simplify CAR-T Detection and Development (1w)

Drug Hunter

• August 2025 (2d)
• BMS-986463 (2d)
• MOMA-341 (3d)
• MRGPRX2 in Immunology - Why is the Field Heating Up? (4d)
• CK-4021586 (5d)
• zolucatetide (FOG-001) (6d)
• Drug-Induced Phototoxicity (6d)
• Basic Pharmacokinetic Principles (1w)
• NVP-IID432 (1w)
• PF-07899895 (1w)

• GLP-1 drugs on WHO Essential Medicines List: what’s the impact? (2d)
• BIOSPAIN 2025: Why 1000 companies from more than 40 countries will gather in Barcelona this year (2d)
• Budget blues: where are cell and gene therapies heading? (4d)
• 10 biotech companies in China you should know about (5d)
• Tapping into the regulatory goldmine: Interview with Ruxandra Teslo (6d)
• Eight biotech career paths where demand is skyrocketing (1w)
• AION Labs is building innovative biotechs with top pharma partners in Israel (1w)
• Kriya Therapeutics has raised $900 million, but for what? (2w)
• When rare diseases are not so rare after all: A closer look at where and why this happens (2w)
• Top biotech deals in August 2025 (2w)

Bio IT World

• NIST Calls for Researchers to Test mRNA Research Grade Test Material (3d)
• Canadian Researchers Measure Insulin Levels for Early Signs of Diabetes, Obesity (4d)
• Drug Delivery Platform Could Usher Phage Therapeutics to the Clinic (5d)
• How The New European Health Data Space Will Drive The Development Of AI-Based Tools (1w)
• Illumina’s Commercial Launch of Proteomics Assay, Acquisiton of SomaLogic (2w)
• First-in-Class Dietary Supplement a Potentially Big Win for Babies (2w)
• Microbiome-Based Therapies Hold Promise for Chronic Diseases (2w)
• Psilocybin Being Investigated as an Anti-Aging Agent (3w)
• Machine Learning Penetrance Score Predicts Genetic Variant Impacts (3w)
• Ultima’s ppmSeq Pushes Sequencing to New Levels of Accuracy (3w)

• Cellares and Technology Provider Team Plan to Expand Cell Q’s Capabilities for Commercial Scale Cell Therapy QC (2d)
• Pancreatic Cancer Slowed by Boosting Cell Surface Sugar in Mice (2d)
• Process Intensification Drives Innovation in Analytical Technologies (2d)
• CRISPR Activation Restores SCN2A Loss, Improves Neurodevelopmental Outcomes in Mice (2d)
• Oral Microbiome Linked to Future Risk of Pancreatic Cancer (2d)
• Boston’s Bioprocessing Buzz: GEN Reports Live from BPI 2025 (3d)
• Needle-Free Vaccine Delivery Enabled by Stretching the Skin (3d)
• Malaria-Transmitting Mosquito’s Genetic Diversity and Evolution Revealed (3d)
• Organoids Recreate Native Kidney Architecture to Model Complex Disease in Mice (3d)
• Optimizing Chromatography for Therapeutic-Antibody Processing (3d)

• MDS Treatment Advances: Targeted Therapies and Anemia Management (3h)
• For Young Adults, A Cancer Diagnosis ‘Doesn’t Define Who You Are’ (23h)
• Lung Cancer Can Affect Anyone, Even Non-Smokers (23h)
• Advances in Kidney Cancer Allow Less Invasive and More Personalized Care (1d)
• MNV-201 Secures FDA Fast Track Designation in Myelodysplastic Syndrome (1d)
• Non-Melanoma Skin Cancer: An Overview From Diagnosis to Treatment (1d)
• FDA Approves Subcutaneous Keytruda in Adult and Pediatric Solid Tumors (2d)
• Welcome to a Survivor’s Yard (2d)
• A Patient Guide to Understanding HER2-Positive Breast Cancer (2d)
• Vaccine Elicits Immune Responses in Pancreatic Cancer (2d)

Contract Pharma*

• Powering Global Access Through an Integrated Supply Chain Infrastructure (2d)
• Roche to Acquire 89bio and Phase 3 MASH Candidate in Potential $3.5B Deal (3d)
• Kindeva Opens New UK HQ and Manufacturing Site (3d)
• Cellares Selects Technology Providers to Expand Cell Q’s Capabilities (3d)
• Wheeler Bio to Support MindImmune’s Alzheimer’s Prevention Program (3d)
• Mabwell Bioscience, Aditum Bio Form Kalexo Bio (3d)
• GSK to Invest $30B in R&D and Manufacturing in the U.S. (3d)
• Quotient Sciences, CPI Form RNA Drug Development Joint Venture (4d)
• Altasciences Recognized for Small Molecule Dosage Form CDMO Services (4d)
• Simtra Purchases 65-Acre Property in Indiana (4d)

• European Commission approves ROMVIMZA for TGCT treatment (3d)
• Modus data on sevuparin for CKD to be presented at global GAG symposium (3d)
• Bimekizumab shows sustained three-year efficacy in hidradenitis suppurativa (4d)
• Nxera and Cancer Research UK begin phase 2a trial of HTL0039732 (4d)
• Imfinzi approved for NHS use in limited-stage small cell lung cance (5d)
• Vorasidenib approved in UK for treating IDH-mutant brain tumours (5d)
• SOM Biotech receives EMA backing for Huntington’s disease drug (6d)
• Capvaxive shows strong immune response in children at risk of pneumococcal disease (1w)
• Lundbeck unveils migraine data for eptinezumab at international congress (1w)
• Rezatapopt shows promise in phase 2 trial for TP53 Y220C solid tumours (2w)

• For Many, CAR T is a Miracle Therapy – We Need to Get it to More Patients (2h)
• Leading Quality Care When The Odds Are Stacked Against You (4h)
• What’s Top of Mind for 3 Healthcare Execs on Deploying AI (1d)
• Scaling Virtual Care Is Both a Moral and Financial Imperative, Sanford Health Exec Says (1d)
• Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease (1d)
• Why We Need to Rethink Private Practice Mental Health Care (2d)
• The Truth About Portals: Why Is Patient Usage so Low? (2d)
• The Top-Ranked Private Cord Blood Banks in the U.S. (2d)
• AI in Healthcare: Investors’ Green and Red Flags Among Startups (2d)
• Roche’s Metabolic Drug Strategy Extends to the Liver Disease MASH With $2.4B 89bio Acquisition (3d)

• CDC committee endorses restrictions on COVID-19 vaccines (1d)
• Preventing radiation damage with melanin-based material (2d)
• This chemist aims to change the game for species conservation (2d)
• CDC advisers endorse changes to MMR, varicella vaccine schedules (2d)
• Quiz: How much do you know about sleep aids? (2d)
• National Academies’ climate report supports endangerment finding, contradicting EPA (2d)
• 2025 Ig Nobel Prizes (2d)
• Breakthrough Energy sees a path through green chemistry's desert (2d)
• Preparing to be in person (3d)
• Syensqo CEO Ilham Kadri to step down (3d)

The Pharma Letter*

• The week in pharma: action, reaction and insight – week to September 19 (5h)
• FDA approves Merck’s Keytruda Qlex (1d)
• FDA accelerated approval for first treatment for Barth syndrome (1d)
• AI-first is not a strategy. It’s how the next generation of pharmaceuticals will operate (2d)
• Aspire Pharma (2d)
• Latest batch of new meds backed for approval by EMA/CHMP (2d)
• EADV data shows Ilumetri’s ‘significant value in long-term holistic management of psoriasis’ (2d)
• Celltrion updates on availability of Omlyclo across Europe (2d)
• Torii Pharma gains Japanese approval for Ycanth (2d)
• FDA delivers three new HAE drugs after four-year drought (2d)

• Potential of Invariant Natural Killer T Cells Spurs Advances in AML (2h)
• Physicians Are Urged to Reclaim Listening as a Clinical Skill (1d)
• Minimal Residual Disease Testing Gains Traction in CLL and Multiple Myeloma (1d)
• Dr Burke on MRD Testing in CLL and Myeloma (1d)
• FDA Approves SC Pembrolizumab for Solid Tumor Indications (2d)
• FDA Fast Tracks MNV-201 in Myelodysplastic Syndromes (2d)
• Larotrectinib Shows Robust Efficacy and Safety in TRK Fusion Cancer (2d)
• DeLLphi-303 Study: Tarlatamab's Impact on Small Cell Lung Cancer (2d)
• FDA Approval Path Remains Unclear for RP1 in Melanoma (2d)
• Carotuximab Shows Promising Early Efficacy in Advanced Prostate Cancer (2d)

• Reviewers Behaving Badly (1d)
• Mirror Life Worries (2d)
• More Legislation to Watch (4d)
• Tuberculosis Defenses (5d)
• Cellular Longevity Through Stress (1w)
• Life, Maybe, On Mars, Unless We Change Our Minds (1w)
• Degunkification (2w)
• Silent RNA (2w)
• An Underappreciated Fate of Drugs in Vivo (2w)
• Stirring Bars are Superstition? (2w)

• Breaking: ACIP pushes back vote on hepatitis B vaccine (2d)
• Biogen buys CNS delivery specialist Alcyone Therapeutics (2d)
• Closed Loop Medicine launches digital GLP-1 dosing platform (2d)
• Lila Sciences' $235m first round, and other biofinancings (2d)
• UK specialists call for more testing on psychedelics (2d)
• ACIP votes against first-dose MMRV for under 4s (2d)
• Regeneron drug on track to be second FOP treatment (3d)
• electronRx cues up launch of digital respiratory platform (3d)
• Oral GLP-1 contest ramps up with new Novo Nordisk data (3d)
• Roche poised to buy MASH drug developer 89bio for $3.5bn (3d)

• This week in Drug Discovery (15 – 19 September) (2d)
• DDW Fall issue out now (2d)
• DDW Highlights: 19 September 2025 (2d)
• DDW Fall 2025 (2d)
• First patient dosed in Phase I trial of antibody-drug conjugate TJ101 (2d)
• Agreement opens new pathways for Lithuanian life science scale-ups (2d)
• Enhanced Genomics receives new funding worth $19 million (2d)
• Study finds safer alternative to CRISPR (2d)
• What’s next for dementia drug research and development? (2d)
• Great Ormond Street Hospital Charity joins cancer research consortium (3d)